Prodrugs and soft drugs.
Prodrugs and soft drugs.
复制标题
DOI：
--
复制
发表时间：
2006-09
期刊：
影响因子：
--
通讯作者：
A. Stańczak;A. Ferra
中科院分区：
文献类型：
--
作者：
A. Stańczak;A. Ferra
本文综述了一种新的药物开发方法，即前药和软药物。如今，我们试图设计出能治愈病人的药物，让病人最容易接受。它们必须在其作用部位上是有效的和选择性的，并且必须被代谢成无毒衍生物。无论是前药还是软性药物，都应具有良好的分布特性，以提高其质量。它们旨在通过改变药物的物理化学，生物制药或药代动力学特性来最大化达到其目标的活性药物的量。前药通过酶或非酶反应在体内转化为活性药物。软药物是已知治疗剂的新型活性类似物。预计继续研究将改善药物性质，以实现最佳的药物递送系统。
This review focuses on a new approach to the development of drugs, namely on prodrugs and soft drugs. Nowadays, we try to design drugs that heal sick people having the best acceptance of patients. They must be efficient and selective on their site of action and must be metabolized to non-toxic derivatives. Both, prodrugs and soft drugs should have good distributive properties to enhance their quality. They are designed to maximize the amount of an active drug that reaches its target, through changing the physicochemical, biopharmaceutical or pharmacokinetic properties of drugs. Prodrugs are changed into the active drug within the body through enzymatic or non-enzymatic reactions. Soft drugs are novel and active analogues of already known therapeutic agents. It is expected that continued studies will improve drug properties so as to achieve the best drug delivery system.